Hubei Biocause Pharmaceutical Statistics

Total Valuation

Hubei Biocause Pharmaceutical has a market cap or net worth of CNY 19.56 billion. The enterprise value is 42.99 billion.

Market Cap	19.56B
Enterprise Value	42.99B

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Hubei Biocause Pharmaceutical has 4.94 billion shares outstanding. The number of shares has increased by 9.74% in one year.

Current Share Class	n/a
Shares Outstanding	4.94B
Shares Change (YoY)	+9.74%
Shares Change (QoQ)	+0.69%
Owned by Insiders (%)	23.32%
Owned by Institutions (%)	3.81%
Float	1.59B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.49
PB Ratio	0.90
P/TBV Ratio	1.27
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-55.70
EV / Sales	1.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.78

Financial Position

The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.49.

Current Ratio	1.95
Quick Ratio	0.98
Debt / Equity	0.49
Debt / EBITDA	n/a
Debt / FCF	-0.73
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -4.32% and return on invested capital (ROIC) is -2.38%.

Return on Equity (ROE)	-4.32%
Return on Assets (ROA)	-0.45%
Return on Capital (ROIC)	-2.38%
Revenue Per Employee	23.06M
Profits Per Employee	-437,319
Employee Count	1,765
Asset Turnover	0.14
Inventory Turnover	9.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.19% in the last 52 weeks. The beta is 0.71, so Hubei Biocause Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	+66.19%
50-Day Moving Average	4.36
200-Day Moving Average	2.80
Relative Strength Index (RSI)	37.18
Average Volume (20 Days)	280,555,554

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hubei Biocause Pharmaceutical had revenue of CNY 40.70 billion and -771.87 million in losses. Loss per share was -0.15.

Revenue	40.70B
Gross Profit	1.68B
Operating Income	-2.15B
Pretax Income	-1.70B
Net Income	-771.87M
EBITDA	-2.04B
EBIT	-2.15B
Loss Per Share	-0.15

Full Income Statement

Balance Sheet

The company has 10.77 billion in cash and 17.56 billion in debt, giving a net cash position of -9.22 billion or -1.87 per share.

Cash & Cash Equivalents	10.77B
Total Debt	17.56B
Net Cash	-9.22B
Net Cash Per Share	-1.87
Equity (Book Value)	36.00B
Book Value Per Share	4.41
Working Capital	16.49B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -24.12 billion and capital expenditures -68.25 million, giving a free cash flow of -24.19 billion.

Operating Cash Flow	-24.12B
Capital Expenditures	-68.25M
Free Cash Flow	-24.19B
FCF Per Share	-4.90

Full Cash Flow Statement

Margins

Gross margin is 4.12%, with operating and profit margins of -5.28% and -1.90%.

Gross Margin	4.12%
Operating Margin	-5.28%
Pretax Margin	-4.18%
Profit Margin	-1.90%
EBITDA Margin	-5.01%
EBIT Margin	-5.28%
FCF Margin	n/a

Dividends & Yields

Hubei Biocause Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.74%
Shareholder Yield	-9.74%
Earnings Yield	-3.89%
FCF Yield	-123.64%

Dividend Details

Stock Splits

The last stock split was on April 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Apr 12, 2010
Split Type	Forward
Split Ratio	2

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a